rs622342 — SLC22A1 A>C

OCT1 rs622342 — The Metformin Transporter Gate

SLC22A1 encodes organic cation transporter 1 (OCT1), the primary transporter responsible for shuttling metformin from the bloodstream into hepatocytes — the liver cells where metformin exerts its glucose-lowering effect. Without efficient OCT1 transport, metformin cannot reach its intracellular target AMP-activated protein kinase (AMPK)¹¹ AMP-activated protein kinase (AMPK)
the master metabolic regulator that suppresses hepatic glucose production, and the drug becomes substantially less effective.

The rs622342 A>C variant sits in an intron of SLC22A1 on chromosome 6. Although intronic, it is believed to affect OCT1 expression or function through linkage disequilibrium with nearby functional variants, or by directly influencing mRNA splicing or transcription factor binding. The C allele tags a haplotype associated with reduced OCT1 transporter activity, diminishing metformin influx into liver cells.

The Mechanism

OCT1 is a polyspecific transporter expressed predominantly on the sinusoidal (blood-facing) membrane of hepatocytes. It mediates the uptake of organic cations including metformin, which carries a positive charge at physiological pH. The rs622342 C allele is associated with reduced OCT1 transporter function — either through decreased protein expression, altered mRNA processing, or linkage with coding variants that impair transporter activity. The net effect is that less metformin enters hepatocytes, reducing activation of AMPK and downstream suppression of hepatic gluconeogenesis.

Beyond metformin, OCT1 transports several other clinically important drugs. Anti-Parkinsonian medications including levodopa, amantadine, and pramipexole are OCT1 substrates, meaning rs622342 genotype can influence their efficacy as well.

The Evidence

The first pharmacogenetic association was established in the Rotterdam Study. Becker et al. 2010²² Becker et al. 2010
Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010 demonstrated that each C allele at rs622342 was associated with a reduced glucose-lowering effect of metformin. The study also revealed a significant multiplicative interaction between OCT1 rs622342 and MATE1 rs2289669 (p=0.015), suggesting that metformin response depends on the combined genotype of its hepatic influx and efflux transporters.

In South Indian type 2 diabetes patients, the association was even more striking. Umamaheswaran et al. 2015³³ Umamaheswaran et al. 2015
Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Clin Exp Med 2015 found that AA homozygotes had 5.6 times greater odds of responding to metformin compared to C allele carriers (OR 3.85 under the dominant model, 95% CI 1.61-9.19). Patients with the A allele achieved approximately 6.3% greater HbA1c reduction after three months of therapy.

A systematic review of 23 studies confirmed that SLC22A1 polymorphisms, including rs622342, significantly influence metformin pharmacokinetics and glycemic control. Systematic review 2024⁴⁴ Systematic review 2024
Influence of SLC22A1 gene polymorphism on metformin pharmacokinetics and HbA1c levels. Curr Diabetes Rev 2024 found rs622342 associated with HbA1c levels in four of six evaluated studies. A separate meta-analysis found a standardized mean difference of -0.45 (95% CI -0.73 to -0.18, p=0.001) for AA versus AC genotypes in HbA1c reduction.

The OCT1 transporter also influences neurological drug response. Becker et al. 2011⁵⁵ Becker et al. 2011
OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics 2011 found that each C allele was associated with 0.34 higher defined daily doses of levodopa between the first and fifth prescriptions (p=0.017), and a 1.47-fold higher mortality ratio after starting levodopa therapy (p=0.045). Average survival was 6.9 years for AA, 5.2 years for AC, and 4.4 years for CC genotype.

Practical Actions

The clinical relevance of rs622342 centers on metformin optimization. For CC homozygotes, the reduced OCT1 function means metformin may provide inadequate glucose-lowering, and alternative or adjunctive diabetes medications should be discussed with the prescribing physician. For AC heterozygotes, metformin response may be somewhat reduced, warranting closer HbA1c monitoring during the first months of therapy.

For individuals on anti-Parkinsonian medications — particularly levodopa, amantadine, or pramipexole — the C allele suggests that higher doses may be needed for therapeutic effect. This information should be shared with the treating neurologist.

Interactions

The most well-documented interaction is between OCT1 rs622342 and MATE1 rs2289669. OCT1 controls metformin influx into hepatocytes, while MATE1 (multidrug and toxin extrusion transporter 1) controls metformin efflux. The combination of reduced OCT1 uptake (rs622342 CC) and altered MATE1 efflux (rs2289669 AA) produces the strongest attenuation of metformin effect — a gene-gene interaction confirmed with p=0.015. Other SLC22A1 variants (rs628031 Met408Val, rs12208357 Arg61Cys, rs34130495 Gly401Ser, rs72552763 Met420del) independently reduce OCT1 function through different mechanisms and may compound with rs622342 to determine overall transporter phenotype.